Compare DexCom, Inc. (DXCM) vs Vanguard Value Index Fund ETF (VTV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Vanguard Value Index Fund ETF — how do they compare? DexCom, Inc. trades at $83.72 (market cap $31.86B), while Vanguard Value Index Fund ETF trades at $220.48 (market cap $262.40B). The key difference: Vanguard Value Index Fund ETF is far larger — about 8.2× DexCom, Inc.'s market cap, and DexCom, Inc. is more actively traded (3,607,070 versus 3,293,281). Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Vanguard Value Index Fund ETF for 142 Days on average.
| DXCM | VTV | |
|---|---|---|
Market Cap | $31.86B | $262.40B |
Volume | 3,607,070 | 3,293,281 |
Sector | Health | — |
52-Week High | $92.34 | $227.51 |
52-Week Low | $54.84 | $182.86 |
Typical Hold Time | 62 Days | 142 Days |
Enterprise Value | $31.32B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $84.3, up 1.09% today, with a bearish technical signal despite strong fundamentals. The company reported Q2 2026 EPS of $0.70, beating estimates, continuing a trend of earnings outperformance. Revenue growth is robust, with 2025 revenue reaching $4.66 billion and net income margin improving to 20.12%. Analyst consensus is strongly bullish with an 80.77% buy rating and a $95.07 price target, suggesting significant upside from current levels.
The outlook for DXCM is positive driven by expansion in continuous glucose monitoring for Type 2 diabetes, as highlighted in recent company reports. Key risks include competitive pressures and reimbursement challenges. With solid cash flow generation and institutional support, the stock presents a growth opportunity, though investors should monitor execution against high expectations.
VTV trades at $219.97, up 0.81% with a bearish technical signal from moving averages. The ETF shows neutral oscillator readings but faces selling pressure from institutional indicators. Recent news highlights value stock outperformance in 2026, with VTV beating growth counterparts by significant margins. The fund offers a 2.3% dividend yield and low 0.03% expense ratio, attracting income-focused investors amid market rotation from growth to value strategies.
VTV presents a compelling value proposition with strong 2026 performance and institutional accumulation. However, technical weakness and long-term underperformance versus broad market indices pose risks. The ETF's low-cost structure and dividend yield support defensive positioning, but investors should weigh recent momentum against historical tracking error concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Vanguard Value Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the CRSP US Large Cap Value Index, a broadly diversified index predominantly made up of value stocks of large US companies. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VTV →
